報價延遲最少15分鐘:2025/07/16 13:38 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.215 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.23/-5.54
|
|
企業價值
1.00B
|
| 資產負債 |
|
每股賬面淨值
5.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
258.00M
|
|
每股收益
1.13
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/16 13:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
